Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.

Title:: Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.
Document type:: Published Erratum
Author(s):: Kundranda, M; Gracian, A C; Zafar, S F; Meiri, E; Bendell, J; Algül, H; Rivera, F; Ahn, E R; Watkins, D; Pelzer, U; Charu, V; Zalutskaya, A; Kuesters, G; Pipas, J M; Santillana, S; Askoxylakis, V; Ko, A H
Journal title abbreviation:: Ann Oncol
Year:: 2020
Journal volume:: 31
Journal issue:: 8
Fulltext / DOI:: doi:10.1016/j.annonc.2020.05.011
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/32507672
Print-ISSN:: 0923-7534
TUM Institution:: Lehrstuhl für Tumormetabolismus (Prof. Algül)
BibTeX

Occurrences: